Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

About this update from Certara, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":235,"url":"https://media.zenfs.com/en/business-wire.com/6d9e276dc332cf60bb1f0d3b15a4f070"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bMzedBawMGhmagMXa1uksA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ3MA--/https://media.zenfs.com/en/business-wire.com/6d9e276dc332cf60bb1f0d3b15a4f070","width":480,"height":235},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Yb6uwU72m2VEP9yBApgOuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMxMw--/https://media.zenfs.com/en/business-wire.com/6d9e276dc332cf60bb1f0d3b15a4f070","width":480,"height":235}},"lazy":false},{"type":"text","content":"LAVAL, Québec & RADNOR, Pa., May 07, 2026--(BUSINESS WIRE)--Altasciences, a fully integrated drug development solution company, and Certara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs.","length":306,"tagName":"p"},{"type":"text","content":"Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach.","length":327,"tagName":"p"},{"type":"text","content":"Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies are refined, and programs are more seamlessly integrated across nonclinical, clinical, bioanalytical, and manufacturing services.","length":560,"tagName":"p"},{"type":"text","content":""At Altasciences, we already help sponsors move from first safety assessment to proof of concept with speed and precision," said Marie-Hélène Raigneau, CEO of Altasciences. "By embedding Certara’s modeling capabilities into our platform, we can further inform critical de...

More updates from Certara, Inc.